Gilead Sciences and Lakefront Biotherapeutics — the Belgian firm formerly known as Galapagos — completed the acquisition of Ouro Medicines on June 4, 2026, expanding Lakefront's inflammation pipeline in a cross-Atlantic deal.1 Lakefront is also co-developing gamgertamig with Gilead, a second strategic track running alongside its newly independent acquisition capacity.
Under deal terms, Lakefront can deploy at least $500 million independently of Gilead and outside the Ouro framework.1 Up to $150 million is earmarked for share buybacks.1 The structure lets Lakefront pursue further acquisitions without requiring Gilead's involvement — an unusual degree of autonomy for a company with a deep U.S. partner.
Ouro's inflammation assets will anchor Lakefront's R&D pipeline going forward.1 The company now runs two simultaneous growth tracks: a co-development partnership with a U.S. pharma giant and a self-directed European-headquartered pipeline.
The deal is part of a wider global consolidation cycle. JAKAFI's 2028 patent cliff is creating urgency among incumbents seeking replacement revenue worldwide. Acquirers are moving earlier into pipelines — buying platforms ahead of Phase 3 data rather than waiting for de-risked assets.
European clinical conferences are reinforcing the deal logic. At EHA 2026, T-cell engagers, in vivo CAR-T platforms, and JAK2 inhibitors produced Phase 2/3 readouts, signaling commercial viability. An FDA PDUFA date for ifinatamab deruxtecan is set for October 2026. Awiqli is approaching U.S. launch — compressing the window between pipeline investment and commercial return.
French radiotherapy firm Nanobiotix offered a benchmark for next-generation efficacy at ESTRO 2026. Its CONVERGE trial reported a 57.1% complete response rate (4 of 7 patients) in Stage 3 inoperable NSCLC.2 The current standard of care achieves complete responses in fewer than 5% of patients.2
German-listed VERAXA Biotech is building discovery infrastructure across bispecific T-cell engagers and bispecific antibody-drug conjugates, applying quality-by-design principles to next-generation antibody formats.3 The platform reflects broad industry investment in multi-specific modalities as successors to approved checkpoint inhibitors.
